Navigation Links
Novavax CEO to Present at BIO Investor Forum 2008
Date:10/28/2008

ROCKVILLE, Md., Oct. 28 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) a clinical-stage vaccine company, announced today that Dr. Rahul Singhvi, President and Chief Executive Officer, will be presenting at the BIO Investor Forum 2008 at 8:30 am. (PT) on October 30, 2008 at the Palace Hotel in San Francisco, California. Dr. Singhvi will provide an overview of the company's strategy, research and development progress. A link to the live presentation can be accessed via the Company website at http://www.novavax.com. An archive of the presentation will be available one hour after the event on the Novavax website for 90 days.

ABOUT NOVAVAX

Novavax, Inc. (Nasdaq: NVAX) is a clinical stage biotechnology company, creating novel vaccines to address a broad range of infectious diseases worldwide using advanced proprietary virus-like particle (VLP) technology. The Company produces these VLP based, potent, recombinant vaccines utilizing new and efficient manufacturing approaches. Additional information about Novavax is available at http://www.novavax.com and in the Company's various filings with the Securities and Exchange Commission.


'/>"/>
SOURCE Novavax, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Novavax Completes Enrollment of Its Seasonal Influenza VLP Vaccine Phase IIa Clinical Trial
2. Novavax Commences Clinical Testing of its Seasonal Influenza VLP Vaccine Candidate
3. Novavax Announces Closing of $18 Million Registered Direct Offering
4. Novavax Announces Pricing of $18 Million Financing of Common Stock and Warrants
5. Novavax to Join Russell 3000 Index
6. Novavax CEO to Present at Piper Jaffray Europe Conference, London, UK
7. Novavax CEO to Present at FBR Capital Markets 12th Annual Spring Investor Conference
8. Novavax CEO to Present at ACUMENBioFins 5th Annual Global Healthcare Conference
9. Novavax Reports First Quarter 2008 Financial Results
10. Novavax Announces Release Date of 2008 First Quarter Financial Results and Investor Conference Call
11. Novavax Opens Its First U.S. Vaccine Plant
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... FREMONT, Calif. , Oct. 30, 2014 /PRNewswire/ ... clinical-stage biopharmaceutical company focused on cardio-renal, gastrointestinal and ... third quarter 2014 financial results on Thursday, November ... team will host a live conference call and ... financial results and provide a business update. ...
(Date:10/30/2014)... Chicago, Illinois (PRWEB) October 30, 2014 ... Regenerative and Cellular Medicine Showcase in Chicago, leading ... and Orthopedic Surgeon, Dr. Wade McKenna presented talks ... Effectiveness and Orthopedic Surgical Applications For Stem Cells. ... of amniotic membrane and the properties of AlphaGEMS ...
(Date:10/30/2014)... James Sherley says he has been working towards ... technology since his days as a principal investigator at the ... 1990’s. Sherley founded the ASCTC as a new Boston ... intellectual property developed in Sherley’s research over the years since ... Technology (MIT), and more recently as a senior scientist at ...
(Date:10/30/2014)... Avure Technologies celebrates a year of success ... of its fleet of high volume High Pressure Processing (HPP) ... we return to PackExpo this year, which is where we ... said Jeff Williams, CEO at Avure. “Sales of the new ... be meeting the challenges of market demand for higher throughput. ...
Breaking Biology Technology:Ardelyx to Report Third Quarter 2014 Financial Results on November 6, 2014 2Riordan-McKenna Institute Founders, Neil Riordan, PhD and Orthopedic Surgeon, Dr. Wade McKenna Present at the Mid American Regenerative and Cellular Medicine Showcase 2Riordan-McKenna Institute Founders, Neil Riordan, PhD and Orthopedic Surgeon, Dr. Wade McKenna Present at the Mid American Regenerative and Cellular Medicine Showcase 3Riordan-McKenna Institute Founders, Neil Riordan, PhD and Orthopedic Surgeon, Dr. Wade McKenna Present at the Mid American Regenerative and Cellular Medicine Showcase 4Boston’s Adult Stem Cell Technology Center, LLC Introduces A New Technology for Monitoring Previously Elusive Adult Stem Cells 2Boston’s Adult Stem Cell Technology Center, LLC Introduces A New Technology for Monitoring Previously Elusive Adult Stem Cells 3Boston’s Adult Stem Cell Technology Center, LLC Introduces A New Technology for Monitoring Previously Elusive Adult Stem Cells 4In High Demand: New High Pressure Processing (HPP) System with Maximum Throughput Drives Strong Sales 2In High Demand: New High Pressure Processing (HPP) System with Maximum Throughput Drives Strong Sales 3
... Since Start of Q4 2008 , - Evaluation of strategic ... Board RoleSAN DIEGO, Jan. 5 ADVENTRX Pharmaceuticals, Inc. (NYSE ... further reduction-in-force in an effort to extend its remaining cash ... follows a reduction implemented in October 2008. In all, ...
... Jan. 5 Theodosius Dobzhansky, the late great geneticist ... makes sense except in the light of evolution."This year ... 1809) and the 150th anniversary of the publication of ... the theory of evolution by means of natural selection ...
... Requadt Promoted From PrincipalsCAMBRIDGE, Mass., and SOUTH SAN ... ("Clarus Ventures"), a leading life sciences venture capital ... M.D., Ph.D., M.P.H., to Partner and Scott Requadt, ... 2009.Dr. Cunningham joined Clarus in 2006 and represents ...
Cached Biology Technology:ADVENTRX Announces Further Cost-Cutting Measures 2ADVENTRX Announces Further Cost-Cutting Measures 3ADVENTRX Announces Further Cost-Cutting Measures 4ADVENTRX Announces Further Cost-Cutting Measures 5GEN Joins Charles Darwin 2009 Celebration 2Clarus Ventures Names Two New Partners 2Clarus Ventures Names Two New Partners 3
(Date:10/29/2014)... household and industrial products are in the environment – ... of them, scientists have yet to determine whether they ... toward doing that by estimating which substances people are ... in the ACS journal Environmental Science & Technology ... the risks to human health of any given substance ...
(Date:10/29/2014)... – As bodies decompose, their types and numbers ... they provide could mean the difference between a ... State University is using a more than $866,000 ... death-scene investigators examine these changing populations. The microbial ... location of death, gender, race, socioeconomic relations and ...
(Date:10/29/2014)... research potential of the Barcode of Life Data ... Biodiversity Data Journal (BDJ) used ... imported these into a human-readable text developed in manuscript ... were used to study the species distributions of ten ... , BOLD is originally designed to support the generation ...
Breaking Biology News(10 mins):MSU partners with Detroit to investigate death scenes 2Go straight and publish: From Barcode of Life Data Systems to scholarly publishing systems 2
... and technical publishing business of John Wiley & Sons, Inc. ... Taipei have signed an agreement to closely cooperate and jointly ... The journal will be available online from volume 2011 in ... collections of online resources, used by 10 million people a ...
... Drying of northern wetlands has led to much more severe ... the atmosphere, according to new research led by a University ... Nature Communications , is the first to investigate the effect ... vulnerability of that carbon to burning. "Russia, Indonesia and ...
... by Dr. Jayne S. Weiss, Professor and Chair of Ophthalmology ... found that a defect in a gene involved in a ... of invasive bladder cancer. The findings are published in the ... Cell Biology . It is the featured research of the ...
Cached Biology News:Journal of the Chinese Chemical Society expands international reach with Wiley-VCH 2Drying intensifying wildfires, carbon release ninefold, study finds 2Mutation in gene associated with rare eye disease also contributes to bladder cancer growth 2
... for maximum packaging efficiencies of T7Select vectors ... (> 109 pfu/g with control DNA) make ... at least 5 107 recombinant plaques ... from a specially designed phage that reduces ...
... delivers enhanced statistics and statistical interpretation ... improvement managers. As an accepted organizational ... simplifies statistics for novice users and ... experts. It offers a powerful JMP ...
... Mouse anti-Yersinia pestis F1 antigen, Monoclonal ... ELISA: Use at an ... an assay dependent dilution. WB: Use ... molecular weight: 18 kDa. Not tested ...
...
Biology Products: